Ep 6- Dispelling Myths About Biosimilars
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Ep 6- Dispelling Myths About Biosimilars
-
Narrated by:
-
By:
About this listen
Biosimilars were first introduced into the US market about six years ago, but getting the all-important “patient buy-in” has been a slow process. Many patients are reluctant to switch to a biosimilar if they’re already happy taking a biologic. But another reason is the proliferation of myths and misinformation about biosimilars, which can be difficult to counteract.
In this episode, Zoe and Conner talk to a few medical professionals about the most common biosimilar falsehoods, and what can be done to stop their spread.
Among the highlights in this episode:
1:58 – The FDA begins cracking down on misinformation
2:47 – Myth #1: Patients confuse biosimilar drugs with generic drugs
3:06 – Doctors’ initial concerns about quality control
3:38 – Hesitancy about ‘transferability’
4:54 – Myth #2: Biosimilars won’t save money
5:50 – Myth #3: Biologics are natural monopolies
Contact Our Hosts:
Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF. zrothblatt@ghlf.org
Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF. cmertens@ghlf.org
We’d love to hear what you think. Send your comments to BreakingDownBiosimilars@GHLF.org
See omnystudio.com/listener for privacy information.